In cancer stem cell and animal models, rebecsinib reversed overactive protein splicing of ADAR1 protein that drives cloning capacity and immune evasion by many malignancies.
Doctors at the University of Chicago Medicine have performed the world's first bilateral stem cell transplant on a patient with drug-resistant bilateral mesial temporal lobe epilepsy (MTLE)